Core Insights - Doctor's Best is a well-established brand in the United States with 35 years of history, appealing to mature and rational consumers through scientific formulations and reliable ingredients [1] - Approximately 80% of Doctor's Best's sales are achieved through well-known online platforms such as Amazon and iHerb in overseas markets, indicating a strong e-commerce presence [1] - The revenue and profit of Doctor's Best have continued to grow in the first three quarters of this year [1]

Core Viewpoint - Kingdawei announced its commitment to the global health industry through biomanufacturing technology, aiming to provide superior nutritional health solutions via technological innovation [1] Company Strategy - The company focuses on building a complete industrial ecosystem, which includes raw material factories, finished product production, and terminal brands [1] - Future plans involve strengthening relevant business segments while leveraging the advantages of a full industry chain layout to enhance synergy between production and branding [1] Industry Positioning - Kingdawei positions itself as a high-tech enterprise dedicated to the global health industry, emphasizing its strategic mission to innovate in health and nutrition [1] - The company aims to expand its influence both domestically and internationally, ensuring a comprehensive approach to its operations [1]

Core Insights - Kingdawei announced on November 5 that its Doctor's Best brand offers a variety of products in China, including those for cardiovascular health, anti-aging, bone strength, and basic vitamins [1] - Popular products include Coenzyme Q10, Ergothioneine, NAD+, Magnesium, Vitamin K, and Vitamin D, along with related compound products [1] - The revenue and profit for Doctor's Best in China have continued to grow in the first three quarters of this year [1] - The company is actively supporting its ongoing Double Eleven sales event [1]

Group 1: Financial Performance - In the first three quarters of 2025, the company achieved a revenue of CNY 2.604 billion, representing a year-on-year increase of 11.16% [2] - The net profit attributable to shareholders was CNY 361 million, showing a significant year-on-year growth of 63.47% [2] - The non-recurring net profit reached CNY 349 million, with a year-on-year increase of 56.22% [2] Group 2: Coenzyme Q10 Performance - Coenzyme Q10 remains a key product, with sales revenue, sales volume, and gross margin all increasing compared to the same period last year [2] - The expansion project for Coenzyme Q10 is progressing smoothly, with the annual production capacity expected to reach a significant volume upon full completion [2][3] - The market demand for Coenzyme Q10 is growing, driven by its applications in cardiovascular health and anti-aging [3] Group 3: Brand Performance - Doctor's Best, a mature brand established 35 years ago in the U.S., has seen revenue and profit growth in the first three quarters of the year [3] - The brand's products, including Coenzyme Q10, are popular among consumers, particularly in categories like cardiovascular health and anti-aging [3] - Doctor's Best is actively participating in promotional activities, such as the Double Eleven event, to enhance its market presence [3] Group 4: Strategic Outlook - The company focuses on biomanufacturing technology and aims to provide high-quality health solutions through innovation [3] - It is committed to building a complete industrial ecosystem, including raw material production, finished product manufacturing, and brand development [3] - Future strategies include strengthening various business segments and leveraging the advantages of a comprehensive supply chain [3]

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-093 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）及子公司厦门金达威维 生素有限公司，近日收到国家知识产权局颁发的 1 件发明专利证书，具体情况如 下： 发明名称：一种 6-氯-6-氧代己酸乙酯的连续制备装置及方法 专利权期限：二十年 证书号：第 8422795 号 授权公告日：2025 年 10 月 31 日 本发明属于有机合成领域，涉及一种 6-氯-6-氧代己酸乙酯的连续制备装置 及方法。本发明提供的 6-氯-6-氧代己酸乙酯的连续制备装置及方法条件温和， 收率高，实现了二氧化硫及氯化氢气体的高效回收，安全可靠，绿色环保，降低 了环境污染，成本低。 上述专利的取得不会对公司生产经营产生重大影响，但有利于公司的技术创 新，充分发挥自主知识产权优势，进一步完善知识产权保护体系，增 ...

南财智讯11月3日电，金达威发布公告称，公司及子公司厦门金达威维生素有限公司近日收到国家知识 产权局颁发的1件发明专利证书。专利名称为"一种6-氯-6-氧代己酸乙酯的连续制备装置及方法"。 ...

金达威公告称，公司及子公司厦门金达威维生素有限公司近日收到国家知识产权局颁发的发明专利证 书，发明名称为"一种6 - 氯 - 6 - 氧代己酸乙酯的连续制备装置及方法"，专利号为ZL202310830368.X， 专利权期限20年。该发明属有机合成领域，条件温和、收率高，能高效回收气体，绿色环保、成本低。 此专利不会对公司经营产生重大影响，但利于技术创新与增强核心竞争力。 ...

Core Viewpoint - The stock price of Kingdawei has experienced fluctuations, with a recent decline of 2.06% and a year-to-date increase of 35.78% [1] Group 1: Stock Performance - As of October 30, Kingdawei's stock price is 19.96 CNY per share, with a market capitalization of 12.174 billion CNY [1] - The stock has seen a net outflow of 694,900 CNY in principal funds, with significant buying and selling activity [1] - Over the past five trading days, the stock has decreased by 3.76%, while it has increased by 5.61% over the past 20 days [1] Group 2: Financial Performance - For the period from January to September 2025, Kingdawei reported a revenue of 2.604 billion CNY, representing a year-on-year growth of 11.16% [2] - The net profit attributable to shareholders for the same period was 361 million CNY, showing a significant increase of 63.47% year-on-year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kingdawei is 36,300, a decrease of 10.95% from the previous period [2] - The average number of circulating shares per shareholder has increased by 12.29% to 16,817 shares [2] - The company has distributed a total of 2.761 billion CNY in dividends since its A-share listing, with 488 million CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [3] - The Southern CSI 1000 ETF and Huaxia CSI 1000 ETF are among the top ten circulating shareholders, with slight changes in their holdings [3]

Core Viewpoint - The performance of the Zhongzheng 1000 ETF Enhanced (561280) shows a positive trend with a year-to-date return of 52.00% since its establishment on August 31, 2023, indicating strong market interest and potential investment opportunities [1] Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced opened at 1.514 yuan, reflecting a 0.46% increase [1] - The fund's performance benchmark is the Zhongzheng 1000 Index return [1] - The fund manager is Industrial Bank of China Credit Fund Management Co., Ltd., with Liu Zihao as the fund manager [1] Group 2: Stock Performance - Key stocks in the fund include: - Boqian New Materials: down 0.17% - Haoyuan Pharmaceutical: up 0.36% - Yingjixin: down 0.31% - Caixun Co.: down 0.28% - Jinma Amusement: up 0.13% - Panjiang Co.: down 0.38% - Jindawei: up 0.20% - Yiyuan Communication: up 0.02% - Minxin Co.: down 5.44% - Nami Technology: down 0.06% [1] Group 3: Recent Returns - The fund has achieved a return of 1.93% over the past month [1]

Core Viewpoint - Kingdawei is a leading global enterprise in coenzyme Q10 with a full industry chain advantage, primarily engaged in the manufacturing of health food and nutritional products [1] Group 1: Business Performance - In Q3 2025, Kingdawei reported revenue of 2.604 billion yuan, ranking 4th in the industry, surpassing the industry average of 1.889 billion yuan and the median of 806 million yuan [2] - The main business segments include health food with revenue of 943 million yuan (54.57%), coenzyme Q10 series with 381 million yuan (22.04%), and vitamin A series with 197 million yuan (11.41%) [2] - The net profit for the same period was 354 million yuan, ranking 2nd in the industry, exceeding the industry average of 194 million yuan and the median of 98.96 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kingdawei's debt-to-asset ratio was 45.31%, an increase from 31.13% year-on-year, and higher than the industry average of 30.87% [3] - The gross profit margin for Q3 2025 was 40.22%, up from 38.03% year-on-year, and above the industry average of 38.90% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 10.95% to 36,300, while the average number of circulating A-shares held per shareholder increased by 12.29% to 16,800 [5] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with notable changes in their holdings [5] Group 4: Growth Prospects - The health product market continues to expand, with Kingdawei's competitive advantages including strengthened raw material supply for health products, increased production capacity of coenzyme Q10 to 920 tons/year, and a focus on R&D with 194 valid patents [5] - Revenue for H1 2025 was 1.728 billion yuan, with a net profit of 247 million yuan, and projected net profits for 2025-2027 are 440 million, 650 million, and 790 million yuan respectively [5][6]